A Chinese corporation spent more than 5,700 billion VND to buy back 64.8% of shares of a Vietnamese pharmaceutical company.

Livzon Pharmaceutical Group Inc (China) has just announced the acquisition of 64.81% of shares at Imexpharm Pharmaceutical Joint Stock Company (stock code: IMP) through the transfer from SK Investment (under SK Group - Korea), Binh Minh Kim Investment Joint Stock Company and KBA Investment Joint Stock Company.

According to the announcement, Livzon Pharmaceutical Group's indirect subsidiary and the seller signed an agreement to purchase a total of 99.8 million IMP shares, accounting for 64.81% of shares at Imexpharm.

Of which, 73.4 million IMP shares are owned by SK Investment; 15 million IMP shares are owned by Binh Minh Kim and 11.3 million IMP shares are owned by KBA Investment.

The estimated value of the deal is nearly VND5,731 billion, of which Livzon will pay SK Investment more than VND4,216 billion, Binh Minh Kim nearly VND863 billion and KBA nearly VND652 billion.

Imexpharm's factory in Vietnam Source: Imexpharm

After the transaction, Livzon Pharmaceutical Group becomes the largest shareholder of Imexpharm.

The reason for the acquisition by Livzon Pharmaceutical Group is said to be to lay a solid foundation for the group's further expansion in foreign markets, supporting its internationalization strategy and sustainable development in the pharmaceutical sector.

On May 23, Imexpharm sent a document to the State Securities Commission and the Ho Chi Minh City Stock Exchange (HoSE) to confirm this transaction.

Livzon Pharmaceutical Group Inc. was founded in 1985 in China. The group is engaged in the research, development, production and sales of pharmaceutical products. .

Meanwhile, Imexpharm, formerly known as Level II Pharmaceutical Company, was established in 1977 in Dong Thap. Currently, this company is the leading pharmaceutical manufacturer in Vietnam, owning 4 factory clusters in Dong Thap, Ho Chi Minh City and Binh Duong , of which 3 factory clusters meet EU-GMP standards with a total of 11 production lines.

In 2024, Imexpharm recorded revenue of VND2,205 billion, up 11% over the previous year. After deducting expenses, the company's after-tax profit reached VND320 billion, up 7% over 2023.

Source: https://nld.com.vn/mot-tap-doan-trung-quoc-chi-hon-5700-ti-dong-mua-lai-648-co-phan-cong-ty-duoc-cua-viet-nam-196250523160428679.htm